LifeCycle Pharma enters its first foreign contract  

2004.04.05
The Danish biotech company has entered its first foreign contract with Recordati to develop a modified-release formulation of Recordati's drug Zanidip

Biotech company LifeCycle Pharma has entered its first foreign contract with the Italian based pharmaceutical company Recordati to develop a modified-release formulation of Recordati's drug Zanidip used for the treatment of hypertension. LifeCycle Pharma will use its MeltDose technology to enhance uptake of the drug by the body. Recordati will pay for the use of Life Cycle Pharma's technology and for pre-clinical development of the drug. LifeCycle Pharma will also receive milestone payments and royalties from sales of the new drug.

 

LifeCycle Pharma's proprietary technology makes it possible to create new formulations and improve existing drugs so that drug patents can be prolonged and thus delay competition from generic drugs. LifeCycle Pharma is a spin-out from pharmaceutical company Lundbeck. Investors include Nordic Biotech, Novo A/S and Lundbeck. The company is located at Hørsholm Science Park close to Copenhagen. The news is reported by BiotechDenmark online and on LifeCycle Pharma's website.

 

Link > LifeCycle Pharma 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×